A randomized study of the safety and pharmacokinetics of GSK3358699, a mononuclear myeloid-targeted bromodomain and extra-terminal domain inhibitor.

Autor: Brown JA; GlaxoSmithKline R&D, Cambridge, MA, USA., Bal J; GlaxoSmithKline R&D Stevenage, Stevenage, UK., Simeoni M; GlaxoSmithKline, GSK House, Brentford, UK., Williams P; GlaxoSmithKline, GSK House, Brentford, UK., Mander PK; GlaxoSmithKline R&D Stevenage, Stevenage, UK., Soden PE; GlaxoSmithKline R&D Stevenage, Stevenage, UK., Daga S; GlaxoSmithKline, Uxbridge, UK., Fahy WA; GlaxoSmithKline, GSK House, Brentford, UK., Wong GK; GlaxoSmithKline R&D Stevenage, Stevenage, UK., Bloomer JC; GlaxoSmithKline R&D, Ware, Hertfordshire, UK., Erwig L; GlaxoSmithKline R&D Stevenage, Stevenage, UK.; Johnson & Johnson, London, UK., Cui Y; GlaxoSmithKline, GSK House, Brentford, UK., Fernando D; GlaxoSmithKline R&D Clinical Unit, Addenbrooke's Hospital, Cambridge, UK., Carnaghan H; GlaxoSmithKline R&D Clinical Unit, Addenbrooke's Hospital, Cambridge, UK., Banham-Hall EJ; GlaxoSmithKline R&D Clinical Unit, Addenbrooke's Hospital, Cambridge, UK., Hopkins S; GlaxoSmithKline R&D Clinical Unit, Addenbrooke's Hospital, Cambridge, UK., Davis BG; GlaxoSmithKline R&D Clinical Unit, Addenbrooke's Hospital, Cambridge, UK., Oliveira JJD; GlaxoSmithKline R&D Clinical Unit, Addenbrooke's Hospital, Cambridge, UK., Prinjha RK; GlaxoSmithKline R&D Stevenage, Stevenage, UK.

Publikováno v: British journal of clinical pharmacology [Br J Clin Pharmacol] 2022 May; Vol. 88 (5), pp. 2140-2155. Date of Electronic Publication: 2021 Dec 18.

Negative Food Effect of Danirixin: Use of PBPK Modelling to Explore the Effect of Formulation and Meal Type on Clinical PK.

Autor: Lloyd RS; Medicinal Science and Technology, GlaxoSmithKline R&D, Park Road, Hertfordshire, UK., Hingle MI; Medicinal Science and Technology, GlaxoSmithKline R&D, Park Road, Hertfordshire, UK., Bloomer JC; Medicinal Science and Technology, GlaxoSmithKline R&D, Park Road, Hertfordshire, UK., Charles SJ; Medicinal Science and Technology, GlaxoSmithKline R&D, Park Road, Hertfordshire, UK., Butler JM; Medicinal Science and Technology, GlaxoSmithKline R&D, Park Road, Hertfordshire, UK., Paul A; Medicinal Science and Technology, GlaxoSmithKline R&D, Park Road, Hertfordshire, UK., Zhu X; Medicinal Science and Technology, GlaxoSmithKline R&D, Collegeville, Pennsylvania, USA., Miller B; Respiratory Therapy Area Unit, GlaxoSmithKline R&D, King of Prussia, Pennsylvania, USA., D'Amico D; Respiratory Therapy Area Unit, GlaxoSmithKline R&D, King of Prussia, Pennsylvania, USA., Donald A; Respiratory Therapy Area Unit, GlaxoSmithKline R&D, King of Prussia, Pennsylvania, USA., Tal-Singer R; Medical Innovation, GlaxoSmithKline R&D, Collegeville, Pennsylvania, USA., Ambery C; Clinical Pharmacology and Modelling Simulation, GlaxoSmithKline R&D, 980 Great West Road, TW8 9GS, Brentford, UK. Claire.l.ambery@gsk.com.

Publikováno v: Pharmaceutical research [Pharm Res] 2020 Oct 29; Vol. 37 (12), pp. 233. Date of Electronic Publication: 2020 Oct 29.

The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist --in healthy adult subjects.

Autor: Miller BE; Clinical Discovery, Respiratory Therapy Area Unit, GlaxoSmithKline R&D, 709 Swedeland Road, King of Prussia, PA, 19406, USA. bruce.e.miller@gsk.com., Mistry S; Clinical Statistics, GlaxoSmithKline R&D, Stockley Park West, Uxbridge, Middlesex, UB11 1BT, UK. sunil.j.mistry@gsk.com., Smart K; Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, London, UK. kevinasmart1@gmail.com.; Roche Pharmaceuticals, Welwyn Garden City, UK. kevinasmart1@gmail.com., Connolly P; Product Development, Platform Technology and Science, GlaxoSmithKline R&D, Park Road, Ware, Hertfordshire, SG 12 0DP, UK. paul.c.connolly@gsk.com., Carpenter DC; Respiratory Therapy Area Unit, GlaxoSmithKline R&D, 709 Swedeland Road, King of Prussia, PA, 19406, USA. donald.c.carpenter@gsk.com., Cooray H; Clinical Pharmacology Sciences and Study Operations, GlaxoSmithKline, London, UK. hiran_CC@hotmail.com.; Global Development, Amgen Inc., Horsham, West Sussex, UK. hiran_CC@hotmail.com., Bloomer JC; Drug Metabolism and Pharmacokinetics, GlaxoSmithKline R&D, Park Road, Ware, Hertfordshire, SG 12 0DP, UK. jackie.c.bloomer@gsk.com., Tal-Singer R; Clinical Discovery, Respiratory Therapy Area Unit, GlaxoSmithKline R&D, 709 Swedeland Road, King of Prussia, PA, 19406, USA. ruth.m.tal-singer@gsk.com., Lazaar AL; Discovery Medicine, Respiratory Therapy Area Unit, GlaxoSmithKline R&D, 709 Swedeland Road, King of Prussia, PA, 19406, USA. aili.l.lazaar@gsk.com.

Publikováno v: BMC pharmacology & toxicology [BMC Pharmacol Toxicol] 2015 Jun 20; Vol. 16, pp. 18. Date of Electronic Publication: 2015 Jun 20.

Impact of physiologically based pharmacokinetic modeling and simulation in drug development.

Autor: Shardlow CE; Department of Drug Metabolism and Pharmacokinetics, GlaxoSmithKline, Ware, Hertfordshire, United Kingdom (C.E.S., A.H.P., J.C.B.), King of Prussia, Pennsylvania (T.T., G.T.), and Research Triangle Park, North Carolina (G.T.G.)., Generaux GT, Patel AH, Tai G, Tran T, Bloomer JC

Publikováno v: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2013 Dec; Vol. 41 (12), pp. 1994-2003. Date of Electronic Publication: 2013 Sep 05.

Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.

Autor: Sakatis MZ; Drug Metabolism and Pharmacokinetics, GlaxoSmithKline , Park Road, Ware, Hertfordshire SG12 0DP, United Kingdom. melanie.z.sakatis@gsk.com, Reese MJ, Harrell AW, Taylor MA, Baines IA, Chen L, Bloomer JC, Yang EY, Ellens HM, Ambroso JL, Lovatt CA, Ayrton AD, Clarke SE

Publikováno v: Chemical research in toxicology [Chem Res Toxicol] 2012 Oct 15; Vol. 25 (10), pp. 2067-82. Date of Electronic Publication: 2012 Sep 19.